ACTRN12622000812796进行中(未招募)未知
First in Human Feasibility Study of Pre-Surgical Embolisation of Hypervascular Extra-axial Brain Tumours with the Arsenal Medical Distal Penetrating Embolic System (DPE) to evaluate initial Safety and Performance.
Arsenal Medical Australia Pty Ltd,0 个研究点目标入组 5 人开始时间: 2022年6月9日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中(未招募)
- 发起方
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 80 Years(—)
- 性别
- All
入选标准
- •Screening Inclusion Criteria:
- •Participant whose age is between 18 and 80 years;
- •Participant whose baseline mRS score is less than or equal to 2;
- •Contrast enhancing extra-axial supratentorial brain tumour measuring between 2.5 cm and 6 cm in the greatest diameter;
- •Participant planned for pre-operative embolisation followed by neurological assessment, and subsequent surgical resection under a separate general anesthesia protocol within the next 7 days;
- •Participant understands the nature of the procedure, consents to participation in the study and provides a signed informed consent form;
- •Participant (woman of child-bearing potential) with a current negative pregnancy test who has agreed to an effective method of contraception throughout the study;
- •Participant is willing to return to or call the investigational site for 30-day and 90-day follow-ups.
- •Baseline Inclusion Criteria:
- •Digital subtractive angiography (DSA) demonstrates a hypervascular tumour blush supplied by branches of the middle meningeal artery which both originates from the external carotid artery and is amenable to catheterisation with a standard microcatheter
- •A negative pregnancy test is required at baseline for a woman of child-bearing potential
排除标准
- •Screening Exclusion Criteria:
- •Tumours originating from the skull base except lateral sphenoid wing
- •Participant who is breastfeeding
- •Participant with life expectancy of less than 1 year
- •Prior embolisation, radiation therapy, or surgical treatment of the tumour
- •Participants with renal impairment that the investigator assesses could be at risk for contrast induced nephropathy
- •Participant with a life-threatening allergy to radiographic contrast (unless treatment for allergy is tolerated or can be managed medically)
- •Participant is allergic to any of the materials used in the DPE device
- •Participant who is currently participating or planning to participate within 3 months in another non-observational clinical research study
- •Baseline Exclusion Criteria:
- •Digital subtractive angiography (DSA) demonstrates vasculature not amenable to catheterisation or embolisation including high-risk anastomoses with eloquent arteries
研究者
相似试验
已完成
不适用
Feasibility and acceptability of pre-operative exercise to improve patient outcomes after major pelvic cancer surgery: A pilot randomised controlled trial.Pelvic CancerCancer - Bowel - Back passage (rectum) or large bowel (colon)Cancer - Ovarian and primary peritonealCancer - Other cancer typesACTRN12617001129370Sydney Local Health District22
进行中(未招募)
不适用
Feasibility and safety of preoperative glucose control in patients with type 2 diabetes undergoing cardiovascular surgeryThe objective of this study is to investigate whether a targeted preoperative glucose control before planned cardiac surgery by i.v. insulin infusion (intensified glycemic control, ICG) versus standard care improves postoperative outcome in patients with T2DM. In addition to evaluating involved molecular mechanisms, this study should also strengthen the evidence of guidelines regarding perioperative glucose management of patients with T2DM.EUCTR2014-000980-42-ATMedical University Vienna40
招募中
Unknown
TetraDERM for Scar ReductioScar ManagementSurgery - Other surgerySkin - Other skin conditionsACTRN12624000965505Tetratherix Technology Pty Ltd45
尚未招募
Unknown
TetraDERM for Scar ReductioScar ManagementSurgery - Other surgerySkin - Other skin conditionsACTRN12624000549527Tetratherix Technology Pty Ltd8
尚未招募
1 期
Feasibility and potential benefits of preoperative chemotherapy with Gemcitabine+nab/Paclitaxel in patients with resectable pancreatic cancer: a multicenter phase I/II trial (APCS-01 study).resectable pancreatic cancerJPRN-UMIN000033901Hirosaki University Graduate School of Medicine30
